HiFiBiO Therapeutics, a Boston, Paris and Shanghai company, has acquired H-Immune, a French biotech with an in vitro immunization-based fully human antibody generation platform (IVI). HiFiBiO has developed its own immunotherapy discovery platform based on single-B-cell screening. It said H-Immune would complement its discovery efforts by identifying first-in-class targets for multiple types of immune cells. H-Immune brings with it a pipeline of novel early stage cancer candidates. Financial details of the acquisition were not disclosed.
Source: China Biotoday
